Bioreactor Enhances Process Control
Sartorius Stedim Biotech’s BIOSTAT Cplus is a fermenter/bioreactor designed for the cultivation of microorganisms and cell cultures. The bioreactor is ideal for process development of vaccines, recombinant protein and monoclonal antibody production, biofuels, and secondary metabolites. Process strategy development can also be applied in batch, fed-batch, and continuous or perfusion operation, as well as scale-up and scale-down experiments. Culture vessels are available in operating volumes of 5, 10, 15, 20, and 30 liters.
A built-in sterilizable-in-place system is equipped with a DCU controller for upstream and downstream processes. The system allows up to four mass flow controllers and up to two scales or gravimetric feed controllers, and includes a pressure hold test to ensure control and safety. Each individual system can be adjusted for application-specific requirements, with automatic pressure control or integrated off-gas measurement options available.
Sartorius Stedim Biotechwww.sartorius.us
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
